
Introducing Acuvía | Connect Collaborate Invest
Acuvía is leveraging the best of AI to break down data barriers and enable health data convergence. Connect with us. Collaborate with us. We’re currently raising funding – invest with us!
Acuvía is leveraging the best of AI to break down data barriers and enable health data convergence. Connect with us. Collaborate with us. We’re currently raising funding – invest with us!
Altheia is pleased to announce that our CEO & Founder, Jolly Nanda, will be pitching to Life Sciences investors at the Bullpen Pitch Fest in August.
A limited number of guest tickets are available for non-Bullpen members for $395 each. If you’re interested in attending, email us at info@altheia.com and we will ensure you receive your guest invitation.
Are you interested in finding out more about Acuvia? Our CEO, Jolly Nanda, will be pitching at the DataTech Startup Showcase on June 7th at the Best Buy headquarters in Richfield, MN. Please make time to see her pitch during the morning session if you’re planning to attend!
We are excited to share that we’ll be at the BETA MN Spring showcase on May 15th, 2024 at the Lumiere in Minneapolis. Please make sure to swing by our booth if you’re planning to attend!
Altheia is excited to announce that we are one of 15 companies selected to participate in the 2024 Spring cohort for BETA MN’s accelerator program.
We are truly excited to be part of this exceptional program with a strong track record for supporting early-stage startups like ours. We hope you’ll stay tuned and follow our journey!
The HHS released is final rule on AI transparency in December 2023. Since its inception, Altheia has been developing our product, Acuvia, with the intention of complying with future rules like this one, as we’ve been anticipating that scrutiny around AI use for decision support in healthcare would continue to grow.
In the first half of this year, we will begin our clinical trial with Acuvia, which is designed to address many concerns around AI use. We will have a 3rd party publish their results of our study, and with our own internal testing, we believe we will be compliant with the regulations as we go to market in 2025.
Here is a summary of the regulations and how Acuvia will comply with them.
Acuvia addresses this in several ways. First, a common dataset is used to ensure that the same information is aggregated for a given population. Second, all information is ingested from valid sources with the individual’s consent. Third, all HIPAA and privacy rules are followed, and the data is secure.
Acuvia generates risk profiles for individuals for 5 chronic diseases. Our predictive models use claims, clinical, and social determinants of health data consented for use by the individuals, who also can augment the dataset with additional information. The member can view all the data used in the creation of their risk profile. Acuvia also presents them with an accuracy metric of how certain the algorithm is about the result. Together, those 2 pieces of data are very useful to help individuals talk to their primary care physicians about their next steps.
Acuvia is an independent utility leveraging member-consented data with the ability to deliver risk stratification results to all stakeholders in the healthcare ecosystem. Its purpose is to provide an accurate assessment of clinical risk associated with 5 chronic diseases, which can be used by both clinicians and individuals to determine the best plan of care to mitigate the effects of disease. The one area where we suggest caution is for the approach used by clinicians from care and disease management companies. Discussing risk for chronic disease with someone who is just finding out that they need to work with their physician on a care management plan requires a well-trained clinical staff equipped to support those critical discussions.
Acuvia has full documentation on all data that was used to train our MVPs for Cardiovascular Disease, CKD, Hypertension, Diabetes and COPD. We also provide an array of reporting at the individual level for individuals as well as at the population segment and full customer levels, including ongoing performance monitoring. Our algorithms use ML and become smarter over time. Our current market approach includes an annual update of all algorithms to ensure our customers will get our most recent versions.
Our product, Acuvia, will move into clinical study and pilot phases in the first half of 2024. We had anticipated that further scrutiny around AI was forthcoming in 2023, so our strategy has been to ensure our product goes through a 3rd party review and is compliant with all rules and regulations related to AI and data security as it enters the market.
We look forward to providing more updates as we launch our clinical study.